Skip to content
Biodatica
Start free

Institut Claudius Regaud

Angers

OncologyFiled/Approved
Compare Sign in to watch

What changed

Phase II trial registered: Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

2mo agoTrial registeredMay 15, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

63 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Nov 17, 2015

    Metastatic Renal Cell Cancer · COMPLETED · sponsor: Institut Claudius Regaud · Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

    ClinicalTrials.gov · NCT02555748 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 13, 2009

    Germ Cell Tumors · COMPLETED · sponsor: Institut Claudius Regaud · Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

    ClinicalTrials.gov · NCT00864318 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Feb 1, 2004

    Genital Neoplasms, Male · COMPLETED · sponsor: Institut Claudius Regaud · Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

    ClinicalTrials.gov · NCT00210041 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources